Eli Lilly and Co’s migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks, the Food and Drug Administration said.

Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1─positive, metastatic non─small cell lung cancer (NSCLC).

Reactie op de consultatie van de Europese Commissie over het vergoedingensysteem van het Europees Geneesmiddelenagentschap (EMA).
Dit document is in het Engels.

Efficacy in the pediatric population with narcolepsy was demonstrated in the Phase 2/3 EXPRESS study (N=106) which included patients aged 7 to 17 years with narcolepsy with cataplexy.